Display options
Cite
Kutcher S, Brooks SJ, Gardner DM, et al. Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatr Dis Treat. 2005;1(2):89-108doi: 10.2147/nedt.1.2.89.61042.
Kutcher, S., Brooks, S. J., Gardner, D. M., Honer, B., Kopala, L., Labelle, A., Lalonde, P., Malla, A., Milliken, H., Soni, J., & Williams, R. (2005). Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatric disease and treatment, 1(2), 89-108. https://doi.org/10.2147/nedt.1.2.89.61042
Kutcher, Stan, et al. "Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders." Neuropsychiatric disease and treatment vol. 1,2 (2005): 89-108. doi: https://doi.org/10.2147/nedt.1.2.89.61042
Kutcher S, Brooks SJ, Gardner DM, Honer B, Kopala L, Labelle A, Lalonde P, Malla A, Milliken H, Soni J, Williams R. Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatr Dis Treat. 2005 Jun;1(2):89-108. doi: 10.2147/nedt.1.2.89.61042. PMID: 18568067; PMCID: PMC2413202.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2005 Jun;1(2):89-108. doi: 10.2147/nedt.1.2.89.61042.

Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.

Neuropsychiatric disease and treatment

Stan Kutcher, Sarah J Brooks, David M Gardner, Bill Honer, Lili Kopala, Alain Labelle, Pierre Lalonde, Ashok Malla, Heather Milliken, Jorge Soni, Richard Williams

Affiliations

  1. Department of Psychiatry Dalhousie University Halifax, NS, [email protected]

PMID: 18568067 PMCID: PMC2413202 DOI: 10.2147/nedt.1.2.89.61042

Abstract

Many atypical antipsychotic medications are becoming available for clinical use. Ziprasidone is a recent addition to this group and is expected to become available for clinical use in Canada in 2005. Ziprasidone has some significant differences compared with other atypicals currently available in Canada. Clinicians need to understand the benefits and risks associated with each of the antipsychotic medications available for the treatment of schizophrenia and related psychotic disorders to ensure their most appropriate utilization. At the suggestion of Professor Stan Kutcher (chair) and as part of an ongoing commitment to provide independent education pertaining to the utility of new psychotropic compounds to health professionals, a panel of Canadian experts in the treatment of schizophrenia spectrum disorders was convened to provide consensus suggestions for the appropriate clinical use of ziprasidone. The consultations regarding the development of these recommendations were organized by Brainworks International (BWI) with arms-length funding from Pfizer Canada. This paper describes the experts' consensus views on the efficacy and safety of ziprasidone, their suggestions on which patients may be suitable for ziprasidone treatment, and how to initiate treatment (including how to switch from other antipsychotic medications), manage side effects, and monitor patients in long-term therapy. These suggestions are those of the authors only and are not endorsed by or necessarily reflect the opinions of BWI or Pfizer Canada.

Keywords: atypical antipsychotic; consensus; psychosis; schizoaffective; schizophrenia; treatment; ziprasidone

References

  1. J Abnorm Psychol. 1975 Jun;84(3):205-9 - PubMed
  2. Schizophr Res. 2004 Feb 1;66(2-3):101-13 - PubMed
  3. Br J Psychiatry. 1998 May;172:413-9 - PubMed
  4. J Pharmacol Exp Ther. 1989 Oct;251(1):238-46 - PubMed
  5. Schizophr Bull. 1987;13(2):261-76 - PubMed
  6. Am J Cardiol. 1993 Aug 26;72(6):10B-13B - PubMed
  7. Schizophr Bull. 1997;23(4):637-51 - PubMed
  8. Schizophr Res. 1992 Mar;6(3):201-8 - PubMed
  9. Schizophr Bull. 2000;26(1):5-20 - PubMed
  10. Schizophr Res. 2004 Jan 1;66(1):51-7 - PubMed
  11. J Clin Psychiatry. 2002;63 Suppl 4:3-11 - PubMed
  12. J Clin Psychopharmacol. 2004 Apr;24(2):192-208 - PubMed
  13. J Clin Psychiatry. 1999 Nov;60(11):767-70 - PubMed
  14. Schizophr Bull. 1999;25(2):233-55 - PubMed
  15. Br J Clin Pharmacol. 2000;49 Suppl 1:71S-76S - PubMed
  16. Psychopharmacology (Berl). 2001 May;155(2):128-34 - PubMed
  17. Am J Cardiol. 1991 Apr 1;67(8):774-6 - PubMed
  18. Br J Clin Pharmacol. 2000;49 Suppl 1:35S-42S - PubMed
  19. Psychopharmacology (Berl). 1998 Nov;140(2):173-84 - PubMed
  20. J Clin Psychiatry. 2003 May;64(5):580-8 - PubMed
  21. Acta Psychiatr Scand. 2000 Sep;102(3):203-10 - PubMed
  22. J Clin Psychiatry. 2002 Dec;63(12):1121-8 - PubMed
  23. J Clin Psychiatry. 2002;63 Suppl 9:18-24 - PubMed
  24. Am J Psychiatry. 2001 Mar;158(3):360-9 - PubMed
  25. J Clin Psychiatry. 2003 May;64(5):598-604 - PubMed
  26. J Clin Psychopharmacol. 1997 Jun;17(3):194-201 - PubMed
  27. J Clin Psychiatry. 2000 Dec;61(12):933-41 - PubMed
  28. Br J Clin Pharmacol. 2000;49 Suppl 1:65S-70S - PubMed
  29. J Clin Psychiatry. 2001 Jan;62(1):12-8 - PubMed
  30. J Cardiovasc Risk. 2001 Aug;8(4):227-33 - PubMed
  31. Schizophr Bull. 1995;21(4):631-43 - PubMed
  32. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13 - PubMed
  33. Acta Psychiatr Scand Suppl. 1970;212:11-9 - PubMed
  34. Br J Psychiatry. 1979 Apr;134:382-9 - PubMed
  35. Epidemiol Rev. 1985;7:105-26 - PubMed
  36. Can J Psychiatry. 1998 Nov;43 Suppl 2:25S-40S - PubMed
  37. Arch Gen Psychiatry. 1999 Mar;56(3):241-7 - PubMed
  38. J Clin Psychiatry. 2002 Jun;63(6):516-23 - PubMed
  39. Am J Psychiatry. 1999 Nov;156(11):1686-96 - PubMed
  40. Drug Metab Dispos. 1997 Jul;25(7):863-72 - PubMed
  41. Am J Psychother. 1986 Jul;40(3):357-69 - PubMed
  42. Am J Health Syst Pharm. 2003 Dec 1;60(23):2437-45 - PubMed
  43. Br J Clin Pharmacol. 2000;49 Suppl 1:15S-20S - PubMed
  44. Br J Psychiatry. 1989 May;154:672-6 - PubMed
  45. J Clin Psychiatry. 2002 Oct;63(10):892-909 - PubMed
  46. Can J Psychiatry. 1997 Mar;42(2):139-51 - PubMed
  47. Am J Psychiatry. 2001 Feb;158(2):176-84 - PubMed
  48. Expert Opin Pharmacother. 2001 Oct;2(10):1655-62 - PubMed
  49. Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56 - PubMed
  50. Can J Cardiol. 1992 Sep;8(7):690-5 - PubMed
  51. J Clin Psychiatry. 2003 Sep;64(9):1133-4 - PubMed
  52. Psychopharmacology (Berl). 1996 Mar;124(1-2):35-9 - PubMed
  53. Can J Psychiatry. 1999 Jun;44(5):464-72 - PubMed
  54. Schizophr Bull. 1984;10(3):388-98 - PubMed
  55. J Clin Psychopharmacol. 2003 Jun;23(3):229-32 - PubMed
  56. JAMA. 2003 Nov 26;290(20):2693-702 - PubMed
  57. Int Clin Psychopharmacol. 2002 Sep;17(5):207-15 - PubMed
  58. Neuropsychopharmacology. 1999 May;20(5):491-505 - PubMed
  59. J Psychiatr Res. 2002 Mar-Apr;36(2):87-95 - PubMed
  60. Bull Am Acad Psychiatry Law. 1986;14(2):105-22 - PubMed
  61. J Clin Psychopharmacol. 2001 Feb;21(1):27-35 - PubMed
  62. Am J Psychiatry. 2002 Oct;159(10):1653-64 - PubMed
  63. J Clin Psychiatry. 2003;64 Suppl 19:6-12 - PubMed
  64. J Clin Psychopharmacol. 2003 Dec;23(6):595-600 - PubMed
  65. Psychiatr Q. 2003 Fall;74(3):277-90 - PubMed
  66. Schizophr Res. 2001 Mar 1;48(1):155-8 - PubMed
  67. Int J Obes Relat Metab Disord. 1996 Oct;20(10):938-42 - PubMed
  68. Ir J Psychol Med. 2003 Mar;20(1):24-27 - PubMed
  69. Schizophr Bull. 1991;17(2):325-51 - PubMed
  70. Psychopharmacol Bull. 1988;24(1):112-7 - PubMed
  71. BMJ. 2000 Dec 2;321(7273):1371-6 - PubMed
  72. Acta Psychiatr Scand Suppl. 1994;382:11-5 - PubMed
  73. J Clin Psychopharmacol. 2004 Feb;24(1):62-9 - PubMed
  74. J Clin Psychiatry. 1998 Feb;59(2):60-8 - PubMed

Publication Types